查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1737058

阿茲海默症市場:治療類別，對症性各適應症，各主要地區

Alzheimer's Disease Market Distribution by Type of Treatment, Symptomatic Indications, and Key Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

預計2030年，全球阿茲海默症市場規模將從目前的124億美元成長至191億美元，預測期內複合年增長率為9%。

市場區隔包括以下市場規模與機會參數：

治療類別

  • 對症療法
  • 緩解疾病

對症性各適應症

  • 失智症
  • 失眠症
  • 其他的生理的症狀

各主要地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

阿茲海默症市場：成長與趨勢

阿茲海默症是一種漸進性神經系統疾病，其特徵是腦細胞死亡，最終導致記憶喪失、認知障礙和失智症。阿茲海默症佔癡呆症病例的60-70%，是美國第六大死因。目前，美國各年齡層約有700萬阿茲海默症患者，預計到2050年這數字將達到約1,300萬人。阿茲海默症的主要症狀包括定向障礙、性格/行為改變、事件/時間/地點混淆以及嚴重的記憶喪失。此外，該病還會導致說話、吞嚥和行走困難。值得注意的是，隨著病情發展，上述症狀會變得更加明顯，最終導致腦細胞死亡。因此，阿茲海默症創新療法的進步為該領域的利益相關者提供了豐厚的利潤。

Alzheimer's Disease Market-IMG1

考慮到阿茲海默症帶來的社會經濟負擔，製藥公司一直在尋找可靠的診斷檢測方法和有效的阿茲海默症治療方案，以減緩疾病的進展。目前，全球已有 160 多家公司積極開發用於治療阿茲海默症的藥物療法。

阿茲海默症市場：關鍵洞察

本報告深入探討了阿茲海默症市場的現狀，並指出了該行業的潛在成長機會。報告的主要發現包括：

  • 目前，全球各地有超過 160 家公司致力於阿茲海默症藥物療法的開發，市場呈現成熟企業和小型企業並存的格局。
  • 目前有超過 240 種藥物療法處於不同的開發階段，正在評估其作為單藥或與其他治療藥物聯合使用的療效，其中大多數為口服給藥。
Alzheimer's Disease Market-IMG2
  • 與阿茲海默症的診斷、治療和管理相關的科學文獻出版數量顯著增加。
  • 與阿茲海默症相關的智慧財產權也在增加，各種實體已提交並授予大量與藥物分子相關的專利。
  • 在過去幾年中，一些組織提供了資金支持，以支持該領域正在進行的研發活動。
  • 在過去十年中，不同地區已開展多項臨床試驗，以評估阿茲海默症的藥物療法，其中許多臨床試驗已經完成。
  • 正在開發的用於治療這種臨床疾病的候選藥物所帶來的好處和機遇，促使一些投資者在近期開發的164個案例中投資了超過40億美元。
  • 阿茲海默症藥物的整體市場機會似乎分佈在不同類型的治療、症狀適應症和主要地區。
Alzheimer's Disease Market-IMG3

阿茲海默症市場:主要市場區隔

阿茲海默症市場：關鍵細分市場

依治療類型，市場分為症狀性治療和疾病改善性治療。目前，疾病改善性治療在全球阿茲海默症市場中佔比最大。此外，症狀性治療市場的成長速度可能比其他細分市場更快。

依症狀適應症，市場分為失智症、失眠症和其他精神症狀。由於用於治療認知症狀的治療藥物數量不斷增加，癡呆症領域目前在全球阿茲海默症市場中佔據最高佔有率。此外，值得注意的是，失眠阿茲海默症市場很可能以相對較高的複合年增長率成長。

依主要地區劃分，市場分為北美、歐洲、亞太地區及世界其他地區。目前，北美在阿茲海默症市場中佔據主導地位，由於該地區良好的監管環境，其收入佔有率最大。事實上，北美監管機構最近批准了幾種新的阿茲海默症藥物，為患者提供了創新的治療方法，並推動了市場的成長。此外，歐洲市場在未來幾年的複合年增長率也可能更高。

本報告提供全球阿茲海默症市場相關調查，提供市場概要，以及治療類別，對症性各適應症，各主要地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 簡介

  • 阿茲海默症概要
  • 阿茲海默症管理:國立衛生研究所實施的計劃
  • 阿茲海默症的管理
  • 阿茲海默症的數位生物標記

第4章 開發平台評估:市售完畢及臨床階段的醫藥品

  • 分析調查手法和主要參數
  • 阿茲海默症治療藥:已上市及開發的開發平台(管線)
  • 阿茲海默症治療藥:開發商一覽

第5章 企業簡介

  • AbbVie
  • AC Immune
  • Biogen
  • Eisai
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Grifols
  • Janssen Pharmaceutical
  • Neurim Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Roche
  • Takeda Pharmaceutical

第6章 案例研究:被廢止了的藥物

  • 章概要
  • 阿茲海默症治療藥:中止的藥物的清單
  • 阿茲海默症治療:中止的臨床試驗的清單
  • 結論

第7章 出版物的分析

第8章 夥伴關係和合作

第9章 資金籌措與投資分析

  • 分析調查手法和主要參數
  • 資金籌措的種類
  • 資金籌措投資分析

第10章 津貼分析

第11章 臨床試驗的分析

第12章 專利分析

第13章 與非藥理學性干預診斷

第14章 與市場規模的評估機會分析

  • 預測調查手法主要的前提條件
  • 全球阿茲海默症市場(到2035年)
  • 到2035年前的全球阿茲海默症市場:治療類別分佈
  • 到2035年前的全球阿茲海默症市場:對症性各適應症分佈
  • 到2035年前的全球阿茲海默症市場:各地區分佈
    • 北美阿茲海默症市場(到2035年)
    • 歐洲的阿茲海默症市場(到2035年)
    • 亞太地區的阿茲海默症市場(到2035年)

第15章 結論

第16章 執行洞察

第17章 附錄1:表格形式資料

第18章 附錄2:企業·團體一覽

Product Code: RA100297

ALZHEIMER'S DISEASE MARKET: OVERVIEW

As per Roots Analysis, the global Alzheimer's disease market is estimated to grow from USD 12.4 billion in the current year to USD 19.1 billion by 2030, at a CAGR of 9% during the forecast period, till 2030.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Treatment

  • Symptomatic
  • Disease Modifying

Symptomatic Indications

  • Dementia
  • Insomnia
  • Other Physiological Symptoms

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

ALZHEIMER'S DISEASE MARKET: GROWTH AND TRENDS

Alzheimer's disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% of cases of dementia, Alzheimer's disease is known to be the sixth leading cause of death in the US. Presently, around seven million Americans of all ages are living with Alzheimer's and this number is projected to reach around 13 million by 2050. The primary symptoms associated with Alzheimer's disease include disorientation, personality / behavioral changes, confusion about events / time / place and severe memory loss. In addition, people suffering from this disease are known to face difficulty in speaking, swallowing and walking. Notably, as the disease progresses, the aforementioned symptoms become more pronounced and contribute to the death of brain cells. Consequently, the advancements in innovative Alzheimer's therapies offer lucrative opportunities to stakeholders engaged in this field.

Alzheimer's Disease Market - IMG1

Given the socioeconomic burden associated with Alzheimer's, pharmaceutical players have been looking for reliable diagnostic tests and effective Alzheimer's treatment alternatives that can slow the progression of this disease. Presently, over 160 companies, based in different regions of the world, have taken initiatives to develop drug therapies for Alzheimer's treatment.

ALZHEIMER'S DISEASE MARKET: KEY INSIGHTS

The report delves into the current state of the Alzheimer's disease market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • Presently, over 160 companies, based in different regions of the world, have taken initiatives to develop drug therapies for Alzheimer's disease; the market is characterized by a mix of well-established and small firms.
  • The pipeline features 240+ drug therapies being evaluated either as monotherapies or in combination with other interventions across different stages of development; most of these are designed for oral administration.
Alzheimer's Disease Market - IMG2
  • There has been a notable increase in published scientific literature related to the diagnosis, treatment and management of Alzheimer's disease.
  • The intellectual property associated with Alzheimer's disease has also increased, as numerous patents related to the drug molecules have been filed by / granted to various organizations.
  • In the past few years, several organizations have extended financial support to aid the ongoing research and development activities in this domain.
  • In the past decade, several clinical trials have been registered for evaluating drug therapies for Alzheimer's disease, across different geographical regions; a number of these trials have already been completed.
  • Several investors have invested over USD 4 billion across 164 instances in the recent past, owing to the benefits and opportunities associated with drug candidates being developed to treat this clinical condition.
  • The overall market opportunity for Alzheimer's disease therapies is likely to be distributed across different types of treatments, symptomatic indications and key geographical regions
Alzheimer's Disease Market - IMG3

ALZHEIMER'S DISEASE MARKET: KEY SEGMENTS

Disease Modifying Segment Occupy the Largest Share of the Global Alzheimer's Disease Market

Based on the type of treatment, the market is segmented into symptomatic and disease modifying types of treatments. At present, the disease modifying segment holds the maximum share of the global Alzheimer's disease market. Further, the symptomatic segment is likely to grow at a faster pace compared to the other segments.

By Symptomatic Indications, Insomnia is the Fastest Growing Segment of the Global Alzheimer's Disease Market During the Forecast Period

Based on the symptomatic indications, the market is segmented into dementia, insomnia, and other psychological symptoms. Currently, the dementia segment captures the highest proportion of the global Alzheimer's disease market owing to the growing number of therapeutic drugs being developed to treat cognitive symptoms. Further, it is worth highlighting that the Alzheimer's disease market for insomnia is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and Rest of the World. Currently, North America dominates the Alzheimer's disease market and accounts for the largest revenue share due to the favorable regulatory environment in this region. In fact, regulatory bodies in North America have recently approved several new Alzheimer's drugs, providing patients with access to innovative therapies and boosting market growth. Additionally, the market in Europe is likely to grow at a higher CAGR in the coming years.

Example Players in the Alzheimer's Disease Market

  • AbbVie
  • AC Immune
  • Biogen
  • Eisai
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Grifols
  • Janssen Pharmaceutical
  • Neurim Pharmaceuticals
  • Novartis
  • Novo Nordisk
  • Roche
  • Takeda Pharmaceutical

ALZHEIMER'S DISEASE MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global Alzheimer's disease market, focusing on key market segments, including [A] type of treatment, [B] symptomatic indications, and [C] key geographical regions.
  • Market Landscape: A comprehensive evaluation of the drugs developed for the treatment of Alzheimer's, based on several relevant parameters, such as [A] current status of development, [B] phase of development of lead candidates, [C] type of biologic, [D] target disease stage, [E] type of treatment, [F] mechanism of action, [G] route of administration, [H] dosing frequency, [I] type of therapy and [J] path to clinic. Additionally, a comprehensive evaluation of the drug developer(s) involved in the domain, based on several relevant parameters, such as [K] year of establishment, [L] company size and [M] geographical location of headquarters.
  • Company Profiles: In-depth profiles of key players engaged in the development of therapeutics for Alzheimer's disease, focusing on [A] overview of the company, [B] financial information (if available), [C] product portfolio, and [D] recent developments and an informed future outlook.
  • Case Study: A detailed discussion on over 110 discontinued drugs and terminated trials, based on various parameters, such as [A] year of discontinuation, [B] reason(s) for discontinuation, [C] phase of discontinuation, [D] mechanism of action of the terminated drugs, [E] type of indication, [F] reason for termination, [G] affiliated stakeholders. Additionally, a detailed assessment of 180 terminated clinical trials, based on various parameters, such as [H] year of termination and [I] key geographies across which these trials were being conducted.
  • Publication Analysis: An insightful analysis of around 20,000 peer-reviewed scientific articles related to research on Alzheimer's disease, based on various relevant parameters, such as [A] year of publication, [B] key focus area, [C] type of molecule, [D] popular keywords, and [E] key journals.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the Alzheimer's disease market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] focus area, [D] type of molecule, [E] most active players (in terms of the number of partnerships signed) and [F] geographical distribution of partnership activity.
  • Funding and Investments: An in-depth analysis of the fundings raised by companies engaged in Alzheimer's disease market, based on relevant parameters, such as [A] year of funding, [B] amount invested, [C] type of funding, [D] geographical analysis, [E] most active players and [F] most active investors.
  • Grants Analysis: A comprehensive assessment of grants that have been awarded to research institutes in the Alzheimer's disease domain, based on various relevant parameters, such as [A] year of grant award, [B] grant amount awarded, [C] administering institute center, [D] support period, [E] type of grant application, [F] grant activity code, [G] emerging focus area, [H] purpose of grant award, [I] type of recent organization, [J] popular NIH department and [K] prominent program officers.
  • Clinical Trial Analysis: An insightful analysis of clinical trials related to therapies being developed for the treatment of Alzheimer's, based on several parameters, such as [A] current trial status, [B] trial registration year, [C] phase of development, [D] study design, [E] leading industry sponsors, [F] study focus, [G] target indication(s), [H] focus areas, [I] target therapeutic area(s), [J] enrolled patient population and [K] regional distribution of trials.
  • Patent Analysis: An in-depth analysis of patents filed / granted till date in the Alzheimer's disease domain, based on various relevant parameters, such as [A] publication year, [B] geography, [C] CPC symbols, [D] emerging focus areas, [E] type of applicant, [F] leading industry players and [G] patent valuation analysis.
  • Non-Pharmacological Interventions and Diagnostics: A detailed discussion on the various non-pharmacological interventions, including [A] cognition / emotion-oriented therapies, [B] sensory simulation therapies and [C] other psychological interventions. Additionally, a discussion of the companies that offer such solutions, providing information on the [D] devices / products and [E] mechanisms of action / working principles.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. An Overview of Alzheimer's Disease
    • 3.1.1. Alzheimer's Disease: Signs and Symptoms
    • 3.1.2. Causes of Alzheimer's Disease
    • 3.1.3. Stages of Alzheimer's Disease
  • 3.2. Alzheimer's Disease Management: Programs Undertaken by The National Institutes of Health
  • 3.3. Alzheimer's Disease Management
  • 3.4. Digital Biomarkers in Alzheimer's Disease
    • 3.4.1. Potential of Digital Biomarkers in Alzheimer's Disease
    • 3.4.2. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer's Disease

4. PIPELINE REVIEW: MARKETED AND CLINICAL- STAGE DRUGS

  • 4.1. Analysis Methodology and Key Parameters
  • 4.2. Alzheimer's Disease Therapies: Marketed and Development Pipeline
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Molecule
    • 4.2.3. Analysis by Target Disease Stage
    • 4.2.4. Analysis by Type of Treatment
    • 4.2.5. Analysis by Mechanism of Action
    • 4.2.6. Analysis by Route of Administration
    • 4.2.7. Analysis by Dosing Frequency
    • 4.2.8. Analysis by Type of Therapy
    • 4.2.9. Analysis by Path to Clinic
    • 4.2.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
  • 4.4. Alzheimer's Disease Therapies: List of Developers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size and Geographical Location of Headquarters
    • 4.4.3. Leading Players: Analysis by Number of Therapies
    • 4.4.4. Analysis by Geography

5. COMPANY PROFILES

  • 5.1. AbbVie
    • 5.1.1. Company Overview
    • 5.1.2. Financial Information
    • 5.1.3. Product Portfolio
    • 5.1.4. Recent Developments and Future Outlook
  • 5.2. AC Immune
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Product Portfolio
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3. Biogen
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Product Portfolio
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4. Eisai
    • 5.4.1. Company Overview
    • 5.4.2. Financial Information
    • 5.4.3. Product Portfolio
    • 5.4.4. Recent Developments and Future Outlook
  • 5.5. Eli Lilly and Company
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Product Portfolio
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. GlaxoSmithKline
    • 5.6.1. Company Overview
    • 5.6.2. Financial Information
    • 5.6.3. Product Portfolio
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Grifols
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Product Portfolio
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Janssen Pharmaceutical
    • 5.8.1. Company Overview
    • 5.8.2. Financial Information
    • 5.8.3. Product Portfolio
    • 5.8.4. Recent Developments and Future Outlook
  • 5.9. Neurim Pharmaceuticals
    • 5.9.1. Company Overview
    • 5.9.2. Financial Information
    • 5.9.3. Product Portfolio
    • 5.9.4. Recent Developments and Future Outlook
  • 5.10. Novartis
    • 5.10.1. Company Overview
    • 5.10.2. Financial Information
    • 5.10.3. Product Portfolio
    • 5.10.4. Recent Developments and Future Outlook
  • 5.11. Novo Nordisk
    • 5.11.1. Company Overview
    • 5.11.2. Financial Information
    • 5.11.3. Product Portfolio
    • 5.11.4. Recent Developments and Future Outlook
  • 5.12. Roche
    • 5.12.1. Company Overview
    • 5.12.2. Financial Information
    • 5.12.3. Product Portfolio
    • 5.12.4. Recent Developments and Future Outlook
  • 5.13. Takeda Pharmaceutical
    • 5.13.1. Company Overview
    • 5.13.2. Financial Information
    • 5.13.3. Product Portfolio
    • 5.13.4. Recent Developments and Future Outlook

6. CASE STUDY: TERMINATED DRUGS

  • 6.1. Chapter Overview
  • 6.2. Alzheimer's Disease Therapies: List of Terminated Drugs
    • 6.2.1. Analysis by Year of Discontinuation
    • 6.2.2. Analysis by Phase of Discontinuation
    • 6.2.3. Analysis by Mechanism of Action
    • 6.2.4. Analysis by Type of Indication
    • 6.2.5. Analysis by Reason for Termination
    • 6.2.6. Analysis by Affiliated Stakeholders
  • 6.3. Alzheimer's Disease Therapies: List of Terminated Clinical Trials
    • 6.3.1. Distribution by Study Start Year and Year of Termination of Clinical Trials
    • 6.3.2. Analysis by Location of Trials
  • 6.4. Concluding Remarks

7. PUBLICATION ANALYSIS

  • 7.1. Analysis Methodology and Key Parameters
  • 7.2. Alzheimer's Disease: List of Publications
  • 7.3. Analysis by Year of Publication
  • 7.4. Analysis by Key Focus Area
  • 7.5. Word Cloud of Study Titles
  • 7.6. Top Journal: Analysis by Number of Publications
  • 7.6. Top Author: Analysis by Number of Publications

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Analysis Methodology and Key Parameters
  • 8.2. Partnership Models
  • 8.3. Alzheimer's Disease: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Type of Partnership and Focus Area of Partnership
    • 8.3.4. Analysis by Type of Partnership and Type of Molecule
    • 8.3.5. Most Active Players: Analysis by Number of Partnerships
    • 8.3.6. Regional Analysis
    • 8.3.7. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Analysis Methodology and Key Parameters
  • 9.2. Types of Funding
  • 9.3. Funding and Investment Analysis
    • 9.3.1. Analysis by Year of Investment
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4 Analysis by Amount Invested Across Different Types of Molecules
    • 9.3.5 Analysis by Amount Invested Across Different Types of Mechanism of Action
    • 9.3.6. Regional Analysis by Amount Invested
    • 9.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 9.3.8. Most Active Investors: Analysis by Amount Funded

10. GRANT ANALYSIS

  • 10.1. Analysis Methodology and Key Parameters
  • 10.2. Alzheimer's Disease: List of Academic Grants
    • 10.2.1. Analysis by Year of Grant Award
    • 10.2.2. Analysis by Grant Amount Awarded
    • 10.2.3. Analysis by Administering Institute Center
    • 10.2.4. Analysis by Support Period
    • 10.2.5. Analysis by Administering Institute Center and Support Year
    • 10.2.6. Analysis by Type of Grant Application
    • 10.2.7. Analysis by Grant Activity Code
    • 10.2.8. Word Cloud of Study Titles
    • 10.2.9. Analysis by Purpose of Grant Award
    • 10.2.10. Analysis by Type of Recipient Organization
    • 10.2.11. Popular NIH Departments: Analysis by Number of Grants
    • 10.2.12. Prominent Program Officers: Analysis by Number of Grants

11. CLINICAL TRIAL ANALYSIS

  • 11.1. Analysis Methodology and Key Parameters
  • 11.2. Alzheimer's Disease: Clinical Trial Analysis
    • 11.3.1. Analysis by Trial Status
    • 11.3.2. Analysis by Trial Registration Year
    • 11.3.3. Analysis by Type of Sponsor / Collaborator
    • 11.3.3. Analysis by Type of Study Design
    • 11.3.4. Analysis by Registration Year and Type of Study
    • 11.3.5. Analysis by Patient Enrollment
    • 11.3.6. Year-wise Trend of Completed and Recruiting Trials
    • 11.3.7. Analysis by Age Category
    • 11.3.8. Word Cloud of Study Titles
    • 11.3.9. Most Active Industry Players: Analysis by Number of Registered Trials
    • 11.3.10. Most Active Non- Industry Players: Analysis by Number of Registered Trials
    • 11.3.11. Analysis by Trial Location
    • 11.3.12. Analysis by Trial Status and Geography

12. PATENT ANALYSIS

  • 12.1. Analysis Methodology and Key Parameters
  • 12.2. Alzheimer's Disease: Patent Analysis
    • 12.2.1. Analysis by Patent Application Year
    • 12.2.2. Analysis by Geography
    • 12.2.3. Analysis by CPC Symbols
    • 12.2.4. Word Cloud: Emerging Focus Areas
    • 12.2.5. Analysis by Type of Applicant
    • 12.2.6. Leading Players: Analysis by Number of Patents
    • 12.2.7 Leading Players: Analysis by Number of International Patents
    • 12.2.8. Patent Valuation Analysis

13. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS

  • 13.1. Non-Pharmacological Interventions for Alzheimer's Disease
    • 13.1.1. Cognition / Emotion-Oriented Interventions
      • 13.1.1.1. Reminiscence Therapy
      • 13.1.1.2. Simulated Presence Therapy
    • 13.1.2. Sensory Stimulation-based Interventions
      • 13.1.2.1. Virtual Reality
      • 13.1.2.2. Music Therapy
      • 13.1.2.3. Light Therapy
      • 13.1.2.4. Aromatherapy
      • 13.1.2.5. Reflexology
    • 13.1.3. Other Psycho-social Interventions
      • 13.1.3.1. Animal-Assisted Therapy

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 14.1. Forecast Methodology and Key Assumptions
  • 14.2. Global Alzheimer's Disease Market, Till 2035
  • 14.3. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Treatment
  • 14.4. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Target Disease Indication
  • 14.5. Global Alzheimer's Disease Market, Till 2035: Distribution by Geography
    • 14.5.1. Alzheimer's Disease Market in North America, Till 2035
      • 14.5.1.1. Alzheimer's Disease Market in North America, Till 2035: Distribution by Type of Treatment
        • 14.5.1.1.1. Alzheimer's Disease Market in North America, Till 2035: Distribution by Symptomatic Treatment
          • 14.5.1.1.1.1. Alzheimer's Disease Market in North America, Till 2035: Share of Dementia in Symptomatic Treatment Market
          • 14.5.1.1.1.2. Alzheimer's Disease Market in North America, Till 2035: Share of Insomnia in Symptomatic Treatment Market
          • 14.5.1.1.1.3. Alzheimer's Disease Market in North America, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
        • 14.5.1.1.2. Alzheimer's Disease Market in North America, Till 2035: Distribution by Disease Modifying Treatment
    • 14.5.2. Alzheimer's Disease Market in Europe, Till 2035
      • 14.5.2.1. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Type of Treatment
        • 14.5.2.1.1. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Symptomatic Treatment
          • 14.5.2.1.1.1. Alzheimer's Disease Market in Europe, Till 2035: Share of Dementia in Symptomatic Treatment Market
          • 14.5.2.1.1.2. Alzheimer's Disease Market in Europe, Till 2035: Share of Insomnia in Symptomatic Treatment Market
          • 14.5.2.1.1.3. Alzheimer's Disease Market in Europe, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
        • 14.5.2.1.2. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Disease Modifying Treatment
    • 14.5.3. Alzheimer's Disease Market in Asia-Pacific, Till 2035
      • 14.5.3.1. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Type of Treatment
        • 14.5.3.1.1. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Symptomatic Treatment
          • 14.5.3.1.1.1. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Dementia in Symptomatic Treatment Market
          • 14.5.3.1.1.2. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Insomnia in Symptomatic Treatment Market
          • 14.5.3.1.1.3. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market
        • 14.5.3.1.2. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Disease Modifying Treatment

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

  • 16.1. Cognition Therapeutics
    • 16.1.1. Company Snapshot
    • 16.1.1. Interview Transcript: Kenneth Moch (President and Chief Executive Officer)
  • 16.2. ArmaGen
    • 16.2.1. Company Snapshot
    • 16.2.2. Interview Transcript: Mathias Schmidt (Chief Executive Officer)
  • 16.2. ICB International
    • 16.2.1. Company Snapshot
    • 16.3.2. Interview Transcript: Ram Bhatt (Chief Executive Officer, Chairman and Founder)

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 Alzheimer's Disease: Marketed and Clinical Development Pipeline
  • Table 4.2 Alzheimer's Disease Therapies: List of Developers
  • Table 6.1 Alzheimer's Disease Therapies: List of Terminated Drugs
  • Table 7.1 Alzheimer's Disease: List of Publications
  • Table 8.1 Alzheimer's Disease: List of Partnerships and Collaborations
  • Table 9.1 Alzheimer's Disease: List of Funding and Investments
  • Table 10.1 Alzheimer's Disease: List of Academic Grants
  • Table 11.1 Alzheimer's Disease: List of Clinical Trials
  • Table 12.1 Alzheimer's Disease: List of Patents
  • Table 17.1. Marketed and Clinical-Stage Drugs: Distribution by Phase of Development
  • Table 17.2. Marketed and Clinical-Stage Drugs: Distribution by Type of Molecule
  • Table 17.3. Marketed and Clinical-Stage Drugs: Distribution by Target Disease Stage
  • Table 17.4. Marketed and Clinical-Stage Drugs: Distribution by Type of Treatment
  • Table 17.5. Marketed and Clinical-Stage Drugs: Distribution by Mechanism of Action
  • Table 17.6. Marketed and Clinical-Stage Drugs: Distribution by Route of Administration
  • Table 17.7. Marketed and Clinical-Stage Drugs: Distribution by Dosing Frequency
  • Table 17.8. Marketed and Clinical-Stage Drugs: Distribution by Type of Therapy
  • Table 17.9. Marketed and Clinical-Stage Drugs: Distribution by Path to Clinic
  • Table 17.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
  • Table 17.11. Alzheimer's Disease Therapies: List of Developers
  • Table 17.12. Alzheimer's Disease Therapy Developers: Distribution by Year of Establishment
  • Table 17.13. Alzheimer's Disease Therapy Developers: Distribution by Company Size and Geographical Location of Headquarters
  • Table 17.14. Leading Players: Distribution by Number of Therapies
  • Table 17.15. Alzheimer's Disease Therapy Developers: Distribution by Geography
  • Table 17.16. AbbVie: Financial Information
  • Table 17.17. AC Immune: Financial Information
  • Table 17.18. Biogen: Financial Information
  • Table 17.19. Eisai: Financial Information
  • Table 17.20. Eli Lilly and Company: Financial Information
  • Table 17.21. GlaxoSmithKline: Financial Information
  • Table 17.22. Grifols: Financial Information
  • Table 17.23. Janssen Pharmaceutical: Financial Information
  • Table 17.24. Neurim Pharmaceuticals: Financial Information
  • Table 17.25. Novartis: Financial Information
  • Table 17.26. Novo Nordisk: Financial Information
  • Table 17.27. Roche: Financial Information
  • Table 17.28. Takeda Pharmaceutical: Financial Information
  • Table 17.29. Terminated Drugs: Distribution by Year of Discontinuation
  • Table 17.30. Terminated Drugs: Distribution by Phase of Discontinuation
  • Table 17.31. Terminated Drugs: Distribution by Mechanism of Action
  • Table 17.32. Terminated Drugs: Distribution by Type of Indication
  • Table 17.33. Terminated Drugs: Distribution by Reason for Termination
  • Table 17.34. Terminated Drugs: Distribution by Affiliated Stakeholders
  • Table 17.35. Terminated Drugs: Distribution by Study Start Year and Year of Termination of Clinical Trials
  • Table 17.36. Terminated Drugs: Distribution by Location of Trials
  • Table 17.37. Publication Analysis: Distribution by Year of Publication
  • Table 17.38. Publication Analysis: Distribution by Key Focus Area
  • Table 17.39. Publication Analysis: Word Cloud of Study Titles
  • Table 17.40. Top Journals: Distribution by Number of Publications
  • Table 17.41. Top Authors: Distribution by Number of Publications
  • Table 17.42. Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 17.43. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.44. Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area of Partnership
  • Table 17.45. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Molecule
  • Table 17.46. Most Active Players: Distribution by Number of Partnerships
  • Table 17.47. Partnerships and Collaborations: Regional Distribution
  • Table 17.48. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 17.49. Funding and Investment Analysis: Distribution by Year of Investment
  • Table 17.50. Funding and Investment Analysis: Distribution by Amount Invested
  • Table 17.51. Funding and Investment Analysis: Distribution by Type of Funding
  • Table 17.52. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Molecules
  • Table 17.53. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Mechanism of Action
  • Table 17.54. Funding and Investment Analysis: Regional Distribution by Amount Invested
  • Table 17.55. Most Active Players: Distribution by Number of Funding Instances
  • Table 17.56. Most Active Investors: Distribution by Amount Funded
  • Table 17.57. Grant Analysis: Distribution by Year of Grant Award
  • Table 17.58. Grant Analysis: Distribution by Grant Amount Awarded
  • Table 17.59. Grant Analysis: Distribution by Administering Institute Center
  • Table 17.60. Grant Analysis: Distribution by Support Period
  • Table 17.61. Grant Analysis: Distribution by Administering Institute Center and Support Year
  • Table 17.62. Grant Analysis: Distribution by Type of Grant Application
  • Table 17.63. Grant Analysis: Distribution by Grant Activity Code
  • Table 17.64. Grant Analysis: Word Cloud of Study Titles
  • Table 17.65. Grant Analysis: Distribution by Purpose of Grant Award
  • Table 17.66. Grant Analysis: Distribution by Type of Recipient Organization
  • Table 17.67. Popular NIH Departments: Distribution by Number of Grants
  • Table 17.68. Prominent Program Officers: Distribution by Number of Grants
  • Table 17.69. Clinical Trial Analysis: Distribution by Trial Status
  • Table 17.70. Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 17.71. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 17.72. Clinical Trial Analysis: Distribution by Type of Study Design
  • Table 17.73. Clinical Trial Analysis: Distribution by Registration Year and Type of Study
  • Table 17.74. Clinical Trial Analysis: Distribution by Patient Enrollment
  • Table 17.75. Clinical Trial Analysis: Year-wise Trend of Completed and Recruiting Trials
  • Table 17.76. Clinical Trial Analysis: Distribution by Age Category
  • Table 17.77. Clinical Trial Analysis: Word Cloud of Study Titles
  • Table 17.78. Most Active Industry Players: Distribution by Number of Registered Trials
  • Table 17.79. Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 17.80. Clinical Trial Analysis: Distribution by Trial Location
  • Table 17.81. Clinical Trial Analysis: Distribution by Trial Status and Geography
  • Table 17.82. Patent Analysis: Distribution by Patent Application Year
  • Table 17.83. Patent Analysis: Distribution by Geography
  • Table 17.84. Patent Analysis: Distribution by CPC Symbols
  • Table 17.85. Word Cloud: Emerging Focus Areas
  • Table 17.86. Patent Analysis: Distribution by Type of Applicant
  • Table 17.87. Leading Players: Distribution by Number of Patents
  • Table 17.88. Leading Players: Distribution by Number of International Patents
  • Table 17.89. Patent Analysis: Patent Valuation Analysis
  • Table 17.90. Non-Pharmacological Interventions for Alzheimer's Disease
  • Table 17.91. Cognition / Emotion-Oriented Interventions
  • Table 17.92. Reminiscence Therapy
  • Table 17.93. Simulated Presence Therapy
  • Table 17.94. Sensory Stimulation-based Interventions
  • Table 17.95. Virtual Reality
  • Table 17.96. Music Therapy
  • Table 17.97. Light Therapy
  • Table 17.98. Aromatherapy
  • Table 17.99. Reflexology
  • Table 17.100. Other Psycho-social Interventions
  • Table 17.12. Animal-Assisted Therapy
  • Table 17.1. Global Alzheimer's Disease Market, Till 2035 (USD Million)
  • Table 17.2. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Treatment (USD Million)
  • Table 17.3. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Target Disease Indication (USD Million)
  • Table 17.4. Global Alzheimer's Disease Market, Till 2035: Distribution by Geography (USD Million)
  • Table 17.5. Alzheimer's Disease Market in North America, Till 2035 (USD Million)
  • Table 17.6. Alzheimer's Disease Market in North America, Till 2035: Distribution by Type of Treatment (USD Million)
  • Table 17.7. Alzheimer's Disease Market in North America, Till 2035: Distribution by Symptomatic Treatment (USD Million)
  • Table 17.8. Alzheimer's Disease Market in North America, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
  • Table 17.9. Alzheimer's Disease Market in North America, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
  • Table 17.10. Alzheimer's Disease Market in North America, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
  • Table 17.11. Alzheimer's Disease Market in North America, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
  • Table 17.12. Alzheimer's Disease Market in Europe, Till 2035 (USD Million)
  • Table 17.13. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Type of Treatment (USD Million)
  • Table 17.17. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Symptomatic Treatment (USD Million)
  • Table 17.15. Alzheimer's Disease Market in Europe, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
  • Table 17.16. Alzheimer's Disease Market in Europe, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
  • Table 17.17. Alzheimer's Disease Market in Europe, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
  • Table 17.18. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
  • Table 17.19. Alzheimer's Disease Market in Asia-Pacific, Till 2035(USD Million)
  • Table 17.20. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Type of Treatment (USD Million)
  • Table 17.21. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Symptomatic Treatment (USD Million)
  • Table 17.22. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Dementia in Symptomatic Treatment (USD Million)
  • Table 17.23. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Insomnia in Symptomatic Treatment (USD Million)
  • Table 17.24. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment (USD Million)
  • Table 17.25. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Disease Modifying Treatment (USD Million)

List of Figures

  • Figure 3.1. Overview of Alzheimer's Disease
  • Figure 3.2. Alzheimer's Disease: Signs and Symptoms
  • Figure 3.3. Causes of Alzheimer's Disease
  • Figure 3.4. Stages of Alzheimer's Disease
  • Figure 3.5. Alzheimer's Disease Management: Programs Undertaken by The National Institutes of Health
  • Figure 3.6. Alzheimer's Disease Management
  • Figure 3.7. Digital Biomarkers in Alzheimer's Disease
  • Figure 3.8. Potential of Digital Biomarkers in Alzheimer's Disease
  • Figure 3.9. Sensors or Digital Senses in Wearable / Mobile Devices for Alzheimer's Disease
  • Figure 4.1. Marketed and Clinical-Stage Drugs: Distribution by Phase of Development
  • Figure 4.2. Marketed and Clinical-Stage Drugs: Distribution by Type of Molecule
  • Figure 4.3. Marketed and Clinical-Stage Drugs: Distribution by Target Disease Stage
  • Figure 4.4. Marketed and Clinical-Stage Drugs: Distribution by Type of Treatment
  • Figure 4.5. Marketed and Clinical-Stage Drugs: Distribution by Mechanism of Action
  • Figure 4.6. Marketed and Clinical-Stage Drugs: Distribution by Route of Administration
  • Figure 4.7. Marketed and Clinical-Stage Drugs: Distribution by Dosing Frequency
  • Figure 4.8. Marketed and Clinical-Stage Drugs: Distribution by Type of Therapy
  • Figure 4.9. Marketed and Clinical-Stage Drugs: Distribution by Path to Clinic
  • Figure 4.10. Grid Analysis: Distribution by Phase of Development, Path to Clinic and Type of Therapy
  • Figure 4.11. Alzheimer's Disease Therapies: List of Developers
  • Figure 4.12. Alzheimer's Disease Therapy Developers: Distribution by Year of Establishment
  • Figure 4.13. Alzheimer's Disease Therapy Developers: Distribution by Company Size and Geographical Location of Headquarters
  • Figure 4.14. Leading Players: Distribution by Number of Therapies
  • Figure 4.15. Alzheimer's Disease Therapy Developers: Distribution by Geography
  • Figure 5.1. AbbVie: Financial Information
  • Figure 5.2. AC Immune: Financial Information
  • Figure 5.3. Biogen: Financial Information
  • Figure 5.4. Eisai: Financial Information
  • Figure 5.5. Eli Lilly and Company: Financial Information
  • Figure 5.6. GlaxoSmithKline: Financial Information
  • Figure 5.7. Grifols: Financial Information
  • Figure 5.8. Janssen Pharmaceutical: Financial Information
  • Figure 5.9. Neurim Pharmaceuticals: Financial Information
  • Figure 5.10. Novartis: Financial Information
  • Figure 5.11. Novo Nordisk: Financial Information
  • Figure 5.12. Roche: Financial Information
  • Figure 5.13. Takeda Pharmaceutical: Financial Information
  • Figure 6.1. Terminated Drugs: Distribution by Year of Discontinuation
  • Figure 6.2. Terminated Drugs: Distribution by Phase of Discontinuation
  • Figure 6.3. Terminated Drugs: Distribution by Mechanism of Action
  • Figure 6.4. Terminated Drugs: Distribution by Type of Indication
  • Figure 6.5. Terminated Drugs: Distribution by Reason for Termination
  • Figure 6.6. Terminated Drugs: Distribution by Affiliated Stakeholders
  • Figure 6.7. Terminated Drugs: Distribution by Study Start Year and Year of Termination of Clinical Trials
  • Figure 6.8. Terminated Drugs: Distribution by Location of Trials
  • Figure 7.1. Publication Analysis: Distribution by Year of Publication
  • Figure 7.2. Publication Analysis: Distribution by Key Focus Area
  • Figure 7.3. Publication Analysis: Word Cloud of Study Titles
  • Figure 7.4. Top Journals: Distribution by Number of Publications
  • Figure 7.5. Top Authors: Distribution by Number of Publications
  • Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area of Partnership
  • Figure 8.4. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Molecule
  • Figure 8.5. Most Active Players: Distribution by Number of Partnerships
  • Figure 8.6. Partnerships and Collaborations: Regional Distribution
  • Figure 8.7. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1. Funding and Investment Analysis: Distribution by Year of Investment
  • Figure 9.2. Funding and Investment Analysis: Distribution by Amount Invested
  • Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 9.4. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Molecules
  • Figure 9.5. Funding and Investment Analysis: Distribution by Amount Invested Across Different Types of Mechanism of Action
  • Figure 9.6. Funding and Investment Analysis: Regional Distribution by Amount Invested
  • Figure 9.7. Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.8. Most Active Investors: Distribution by Amount Funded
  • Figure 10.1. Grant Analysis: Distribution by Year of Grant Award
  • Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded
  • Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
  • Figure 10.4. Grant Analysis: Distribution by Support Period
  • Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Year
  • Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
  • Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
  • Figure 10.8. Grant Analysis: Word Cloud of Study Titles
  • Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 10.10. Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 10.11. Popular NIH Departments: Distribution by Number of Grants
  • Figure 10.12. Prominent Program Officers: Distribution by Number of Grants
  • Figure 11.1. Clinical Trial Analysis: Distribution by Trial Status
  • Figure 11.2. Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 11.3. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 11.4. Clinical Trial Analysis: Distribution by Type of Study Design
  • Figure 11.5. Clinical Trial Analysis: Distribution by Registration Year and Type of Study
  • Figure 11.6. Clinical Trial Analysis: Distribution by Patient Enrollment
  • Figure 11.7. Clinical Trial Analysis: Year-wise Trend of Completed and Recruiting Trials
  • Figure 11.8. Clinical Trial Analysis: Distribution by Age Category
  • Figure 11.9. Clinical Trial Analysis: Word Cloud of Study Titles
  • Figure 11.10. Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 11.11. Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 11.12. Clinical Trial Analysis: Distribution by Trial Location
  • Figure 11.13. Clinical Trial Analysis: Distribution by Trial Status and Geography
  • Figure 12.1. Patent Analysis: Distribution by Patent Application Year
  • Figure 12.2. Patent Analysis: Distribution by Geography
  • Figure 12.3. Patent Analysis: Distribution by CPC Symbols
  • Figure 12.4. Word Cloud: Emerging Focus Areas
  • Figure 12.5. Patent Analysis: Distribution by Type of Applicant
  • Figure 12.6. Leading Players: Distribution by Number of Patents
  • Figure 12.7 Leading Players: Distribution by Number of International Patents
  • Figure 12.8. Patent Analysis: Patent Valuation Analysis
  • Figure 13.1. Non-Pharmacological Interventions for Alzheimer's Disease
  • Figure 13.2. Cognition / Emotion-Oriented Interventions
  • Figure 13.3. Reminiscence Therapy
  • Figure 13.4. Simulated Presence Therapy
  • Figure 13.5. Sensory Stimulation-based Interventions
  • Figure 13.6. Virtual Reality
  • Figure 13.7. Music Therapy
  • Figure 13.8. Light Therapy
  • Figure 13.9. Aromatherapy
  • Figure 13.10. Reflexology
  • Figure 13.11. Other Psycho-social Interventions
  • Figure 13.12. Animal-Assisted Therapy
  • Figure 14.1. Global Alzheimer's Disease Market, Till 2035 (USD Million)
  • Figure 14.2. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Treatment (USD Million)
  • Figure 14.3. Global Alzheimer's Disease Market, Till 2035: Distribution by Type of Target Disease Indication (USD Million)
  • Figure 14.4. Global Alzheimer's Disease Market, Till 2035: Distribution by Geography (USD Million)
  • Figure 14.5. Alzheimer's Disease Market in North America, Till 2035 (USD Million)
  • Figure 14.6. Alzheimer's Disease Market in North America, Till 2035: Distribution by Type of Treatment (USD Million)
  • Figure 14.7. Alzheimer's Disease Market in North America, Till 2035: Distribution by Symptomatic Treatment (USD Million)
  • Figure 14.8. Alzheimer's Disease Market in North America, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
  • Figure 14.9. Alzheimer's Disease Market in North America, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
  • Figure 14.10. Alzheimer's Disease Market in North America, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
  • Figure 14.11. Alzheimer's Disease Market in North America, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
  • Figure 14.12. Alzheimer's Disease Market in Europe, Till 2035 (USD Million)
  • Figure 14.13. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Type of Treatment (USD Million)
  • Figure 14.14. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Symptomatic Treatment (USD Million)
  • Figure 14.15. Alzheimer's Disease Market in Europe, Till 2035: Share of Dementia in Symptomatic Treatment Market (USD Million)
  • Figure 14.16. Alzheimer's Disease Market in Europe, Till 2035: Share of Insomnia in Symptomatic Treatment Market (USD Million)
  • Figure 14.17. Alzheimer's Disease Market in Europe, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment Market (USD Million)
  • Figure 14.18. Alzheimer's Disease Market in Europe, Till 2035: Distribution by Disease Modifying Treatment (USD Million)
  • Figure 14.19. Alzheimer's Disease Market in Asia-Pacific, Till 2035(USD Million)
  • Figure 14.20. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Type of Treatment (USD Million)
  • Figure 14.21. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Symptomatic Treatment (USD Million)
  • Figure 14.22. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Dementia in Symptomatic Treatment (USD Million)
  • Figure 14.23. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Insomnia in Symptomatic Treatment (USD Million)
  • Figure 14.24. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Share of Other Psychological Symptoms in Symptomatic Treatment (USD Million)
  • Figure 14.25. Alzheimer's Disease Market in Asia-Pacific, Till 2035: Distribution by Disease Modifying Treatment (USD Million)